Genetically encoded inhibitors for voltage-dependent Ca 2+ (Ca V ) channels (GECCIs) are useful research tools and potential therapeutics. Rad/Rem/Rem2/Gem (RGK) proteins are Ras-like G proteins that potently inhibit high voltage-activated (HVA) Ca 2+ (Ca V 1/Ca V 2 family) channels, but their nonselectivity limits their potential applications. We hypothesized that nonselectivity of RGK inhibition derives from their binding to auxiliary Ca V β-subunits. To investigate latent Ca V β-independent components of inhibition, we coexpressed each RGK individually with Ca V 1 (Ca V 1. 62%, respectively, of HVA currents in somatosensory neurons of the dorsal root ganglion, corresponding to their distinctive selectivity for Ca V 1.2 and Ca V 1.2/Ca V 2.2 channels. Thus, we have exploited latent β-binding-independent Rem and Rad inhibition of specific Ca V 1/Ca V 2 channels to develop selective GECCIs with properties unmatched by current small-molecule Ca V channel blockers.
H igh voltage-activated (HVA) Ca 2+ (Ca V ) channels convert electrical signals into Ca 2+ influx that controls myriad essential processes including neuronal communication, muscle contraction, hormone release, and activity-dependent gene transcription (1) . HVA Ca V channels are composed of a pore-forming α 1 -assembled with auxiliary β-, α 2 δ-, and γ-subunits and calmodulin. There are seven α 1 -subunits (Ca V 1.1 to 1.4 and Ca V 2.1 to 2.3), four Ca V βs (β 1 to β 4 ), and three α 2 δs (α 2 δ1 to α 2 δ3), each with multiple splice variants. Ca V α 1 -subunits contain the voltage sensor, selectivity filter, and channel pore, while auxiliary subunits regulate channel properties-Ca V βs are obligatory for α 1 -trafficking to the plasma membrane and for modulating channel gating (2); α 2 δs enhance channel surface trafficking and also modulate channel gating (3); and calmodulin promotes channel trafficking, enhances basal open probability (P o ), and confers feedback Ca 2+ regulation of channel gating (4, 5) . Ca V channels are also regulated by various intracellular signaling proteins and posttranslational modifications as a mechanism to control physiology. Pharmacological blockade of Ca V 1/ Ca V 2 channels is an important treatment strategy for diverse diseases including hypertension, cardiac arrhythmias, chronic pain, and Parkinson's disease (1) . RGK proteins (Gem, Rad, Rem, and Rem2) are small Ras-like G proteins that bind Ca V β-subunits and profoundly inhibit all Ca V 1/Ca V 2 channels (6-8).
Given their properties, RGKs straddle two worlds with respect to their impact on Ca V 1/Ca V 2 channels-they are (i) potentially powerful physiological regulators by virtue of their capacity to tune intracellular Ca 2+ signals, and (ii) prototype genetically encoded Ca V channel blockers with possible therapeutic and biotechnological applications (9) . Consistent with important physiological roles, Rad knockout mice exhibit increased cardiac Ca V 1.2 currents and cardiac hypertrophy, while Gem-deficient mice display glucose intolerance and impaired glucose-stimulated insulin release. Regarding their use as potential therapeutics, expression of Gem in the atrioventricular node was effective at electrically uncoupling ventricular excitation from the fibrillating atria in a porcine model of atrial fibrillation (10) . A Rem derivative engineered to selectively target and inhibit caveola-localized Ca V channels effectively inhibited pacinginduced NFATc3-GFP translocation to the nucleus in adult feline ventricular cardiomyocytes, without affecting excitation-contraction coupling (11) .
A major limitation for the use of RGKs as genetically encoded Ca V channel blockers involves their lack of selectivity for particular Ca V 1/Ca V 2 isoforms. Rem inhibits Ca V 1.2 channels using multiple mechanisms including reduced channel surface density, diminished P o , and partial immobilization of voltage sensors (12) . At least one of these mechanisms (decreased P o ) involves the simultaneous association of Rem with the auxiliary Ca V β-subunit and the plasma membrane (13, 14) . This mechanism
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likely accounts for the indiscriminate nature of RGK inhibition of Ca V 1/Ca V 2 channels, since all four RGKs bind Ca V β-subunits and the plasma membrane, and Ca V βs are obligatory for forming functional channels. Beyond the β-binding mechanism, we previously showed that Rem can also inhibit Ca V 1.2 channels by directly binding to the pore-forming α 1C -subunit (15) . Potentially, such an α 1 -subunit-dependent mechanism could be exploited to develop genetically encoded Ca V 1/Ca V 2 isoform-selective inhibitors. Several outstanding questions need to be addressed to realize this potential. Does Rem inhibit other Ca V 1/Ca V 2 channels beyond Ca V 1.2 in a β-binding-independent manner? Do other RGKs beyond Rem inhibit Ca V 1/Ca V 2 channel isoforms in a β-binding-independent manner? Are both β-binding-dependent and β-binding-independent mechanisms of RGK inhibition of particular Ca V 1/Ca V 
Results
Differential Prevalence of β-Binding-Dependent and β-BindingIndependent Rem Inhibition Across Distinct Ca V 1/Ca V 2 Channels. We profiled β-binding-dependent (BBD) and β-binding-independent (BBI) Rem inhibition of Ca V channels by reconstituting distinct pore-forming α 1 -subunits with either wild-type β 2a or a mutant β 2a (β 2a,TM ) that does not bind RGKs. HEK293 cells expressing α 1C + β 2a expressed robust Ba 2+ currents (I Ba ) that were virtually eliminated when Rem was coexpressed ( Fig. 1 A and B and SI Appendix, Fig. S1 ). Similarly, cells expressing α 1C + β 2a,TM displayed I Ba that was significantly inhibited by Rem ( Fig. 1 A and B and SI Appendix, Fig. S1 ), indicating the incidence of both BBD and BBI Rem inhibition of Ca V 1.2 channels. These results confirm our previous report that both BBD and BBI mechanisms contribute to Rem inhibition of Ca V 1.2 (15) . I Ba influx through reconstituted Ca V 1.3 channels (α 1D + β 2a ) was eliminated by Rem. However, Ca V 1.3 channels reconstituted with α 1D + β 2a,TM were refractory to Rem ( Fig. 1 C and D and SI Appendix, Fig. S1 ), indicating the absence of BBI inhibition, and revealing a fundamental difference from Ca V 1.2. Similar to Ca V 1.3, Ca V 2.1 ( Fig. 1 E and F and SI Appendix, Fig. S1 ) and Ca V 2.2 ( Fig. 1 G and H and SI Appendix, Fig. S1 ) channels were inhibited by Rem only when reconstituted with WT β 2a , but not β 2a,TM , a modulation profile consistent with exclusively BBD inhibition.
Engineering a Ca V 1.2-Selective Inhibitor from Rem. The finding that BBI Rem inhibition of I Ba is a unique property of Ca V 1.2 suggested the possibility of engineering a Ca V 1.2-selective genetically encoded inhibitor by generating a Rem mutant that does not bind Ca V β. A previous mutagenesis study identified residues in RGKs that were critical for their interaction with Ca V βs but did not disrupt their tertiary structure, as evaluated by GTP/ GDP binding assays (16) . Based on these findings, we introduced two point mutations (R200A, L227A) into Rem and used FRET to evaluate the association of Rem[R200A/L227A] with Ca V β ( Beqollari et al. (17) .
To determine whether Rem[R200A/L227A] could inhibit endogenous Ca V 1.2 channels, we assessed its efficacy in blocking I Ba conducted through native Ca V 1.2 channels in guinea pig ventricular cardiomyocytes. We generated adenovirus enabling robust expression of YFP-Rem[R200A/L227A] (Fig. 2E) . Compared with control cells expressing GFP, cardiomyocytes expressing YFP-Rem[R200A/L227A] displayed a significantly reduced I Ba at all test voltages (Fig. 2 F and G; I peak,0mV = 22.6 ± 4.6 pA/pF, n = 8 for GFP compared with I peak,0mV = 9.1 ± 2.3 pA/pF, n = 10, for YFP-Rem[R200A/L227A]), thus demonstrating BBI Rem inhibition of endogenous Ca V 1.2 channels in the heart.
Prevalence of BBD and BBI RGK Inhibition Across the Ca V 1/Ca V 2 Channel Family. We wondered whether other RGKs display BBI inhibition of Ca V 1/Ca V 2 channels that could be similarly exploited to generate selective genetically encoded inhibitors for Ca V channels (GECCIs). We profiled the occurrence of BBD and BBI inhibition across RGKs and Ca V 1/Ca V 2 channels by assessing the impact of Gem, Rad, and Rem2 on recombinant Ca V channels reconstituted with either WT β 2a or β 2a,TM (Fig. 3A and SI Appendix, Fig. S3 ). Ca V 1.3 channels reconstituted with WT β 2a (α 1D + β 2a ) were uniformly inhibited by Gem, Rad, and Rem2, respectively (SI Appendix, Fig. S3B ). By contrast, these three RGKs had no impact on I Ba influx through α 1D + β 2a,TM channels (SI Appendix, Fig. S3B ). Together, these results indicate that all RGKs inhibit Ca V 1.3 channels solely through a BBD mechanism. We obtained virtually identical results with reconstituted Ca V 2.1 channels-α 1A + β 2a channels were inhibited by Gem, Rad and Rem2, whereas α 1A + β 2a,TM channels were refractory to these RGKs (SI Appendix, Fig. S3C ). Hence, Ca V 2.1 channels also display exclusively BBD RGK inhibition. The finding that Rem2 inhibits Ca V 2.1 in a solely BBD manner agrees with a previous result showing that Rem2 abolishes current through Ca V 2.1 channels reconstituted with WT β 4 but not a mutant β 4 lacking the capacity to bind Rem2 (18) . Our finding that Gem requires binding to Ca V β to decrease Ca V 2.1 is in disagreement with a previous report that Gem binding to Ca V β 3 was not necessary for its capacity to inhibit Ca V 2.1 current (19) . The reasons for this discrepancy are unclear, though one possibility is the intrinsic differences between Xenopus oocytes (used in the previous study) and the mammalian cells used here. As expected, wild-type Ca V 2.2 channels (α 1B + β 2a ) were robustly inhibited by Gem, Rad, and Rem2, respectively. Interestingly, while channels reconstituted with α 1B + β 2a,TM were unaffected by Gem and Rem2, they were significantly inhibited by Rad (Fig. 3B) . Therefore, Rad uniquely mediates both BBD and BBI inhibition of Ca V 2.2 channels. We previously reported that Rad (but not Gem or Rem2) also supports BBD and BBI inhibition of Ca V 1.2 (15) 3 showed lower FRET efficiency (0.051 ± 0.002, n = 142) compared with CFP-Rad + YFP-β 3 (0.123 ± 0.004, n = 174) (Fig. 4B) . Binding-curve analyses indicated an eightfold decrease in affinity of CFP-Rad[R208A/L235A] for YFP-β 3 compared with CFP-Rad (Fig. 4C) . As predicted, Rad[R208A/L235A] significantly inhibited currents through recombinant Ca V 1.2 (α 1C + β 2a ) and Ca V 2.2 (α 1B + β 2a ) channels but had no impact on either Ca V 1.3 (α 1D + β 2a ) or Ca V 2.1 (α 1A + β 2a ) channels (Fig. 4D and SI Appendix, Fig. S4) (Fig. 4 E and F) , revealing a strong BBI Rad inhibition of Ca V 1.2 in the heart. It was previously shown that Rad-inhibited Ca V 1.2 channels are not up-regulated by activated protein kinase A (PKA) (20) . We found that I Ba through ventricular Ca V 1.2 channels inhibited by Rad[R208A/L235A] was robustly increased by 1 μM forskolin, in sharp contrast to the lack of modulation observed with WT Rad-inhibited channels (Fig. 4 G and H and SI  Appendix, Fig. S5) (21). We used adenoviral vectors to robustly express GFP (control) or CFP-tagged RGKs in cultured mouse DRG neurons (Fig. 5A) . In control cells, a ramp protocol elicited two components of I Ba , reflecting currents through LVA and HVA Ca V channels, respectively. Overexpressing WT Rad essentially eliminated the HVA current component while leaving the LVA element intact (Fig. 5B) . We further assessed the impact of various WT and mutant RGKs on the HVA Ca V channel currents using step depolarizations. For these experiments, LVA Ca V channel currents were eliminated by 5 μM mibefradil and a −50-mV holding potential. Control DRG neurons displayed HVA I Ba currents which were dramatically reduced by WT Rad (Fig. 5 C and D; I peak,−10mV = −76.5 ± 13.8 pA/pF, n = 10 for GFP compared with I peak,−10mV = −3.5 ± Similar to WT Rad, DRG neurons expressing either CFP-Rem or CFP-Gem showed a dramatically reduced HVA I Ba amplitude ( Fig. 5D ; I peak,−10mV = −8.7 ± 3.8 pA/pF, n = 8 for CFP-Rem, and I peak,−10mV = −4.8 ± 0.9 pA/pF, n = 4 for CFP-Gem; SI Appendix, Fig. S6 ). Expressing CFP-Rem[R200A/L227A] depressed HVA I Ba by 25% compared with control ( Fig. 5D ; I peak,−10mV = −56.5 ± 6.6 pA/pF, n = 13; SI Appendix, Fig. S6 ), substantially less than the reduction observed with CFP-Rad[R208A/L235A]. By contrast, Gem[R196A/V223A] had no impact on HVA I Ba in DRG neurons ( Fig. 5D ; I peak,−10mV = −74.5 ± 15.4 pA/pF, n = 12; SI Appendix, Fig. S6) . Overall, the rank order of inhibition of HVA I Ba by these mutant RGKs is consistent with the notion that CFP-Rad[R208A/L235A] inhibits both Ca V (24) . Prialt (ziconotide), a blocker of Ca V 2.2 derived from a marine snail conotoxin, is Food and Drug Administration-approved for the treatment of chronic pain (25) . The use of small-molecule Ca V 1/Ca V 2 channel blockers is mainly limited by two factors. First, Ca V 1/Ca V 2 expression in many types of excitable cells risks prohibitive off-target effects. Second, due to a high degree of similarity among pore-forming α 1 -subunits (e.g., the L-type channels, Ca V 1.1 to Ca V 1.4), currently available small-molecule blockers may not effectively distinguish between Ca V channels of the same class. Difficulties encountered in developing Ca V 1.3-selective blockers as a potential treatment for Parkinson's disease exemplify these challenges (26, 27) . Efficacy of such a treatment approach was suggested by reports that the reliance of substantia nigra neurons on Ca V 1.3 for pacemaking made them sensitive to Ca 2+ overload and vulnerable to cell death which drives the development of Parkinson's disease (28, 29) . Epidemiological studies suggest indeed some beneficial effects of L-type calcium channel (LTCC) blockers in Parkinson's disease (30) . However, because the currently available LTCC blockers are not selective for Ca V 1.3, off-target effects (e.g., on cardiovascular Ca V 1.2 channels) risk serious side effects such as hypotension, significantly narrowing the therapeutic window (31) .
Genetically encoded Ca V channel blockers could offer an alternative solution without the above-mentioned drawbacks of small-molecule inhibitors. Off-target effects might be avoided by restricted expression in target tissues or defined cell populations (9, 10) . RGKs are promising candidates for such an alternative treatment approach, given their potency as Ca V channel blockers. Their potential usefulness is twofold: (i) as endogenous GECCIs for therapeutic or biotechnological applications, and (ii) as natural prototypes that can help inform strategies to design novel GECCIs for targeted applications in diseases involving excitable cells. Regarding the former, the indiscriminate nature of RGK inhibition of all Ca V 1/Ca V 2 channels represents a potential obstacle for some applications. We tested here whether selectivity for particular Ca V 1/Ca V 2 isoforms could be engineered into RGKs. Based on the intuition that the indiscriminate manner with which RGKs inhibit all Ca V 1/Ca V Additionally, our experiments revealed the existence of BBI mechanisms underlying Rem and Rad inhibition of Ca V 1/Ca V 2 channels in excitable cells. This raises the question of the biological significance of BBD versus BBI Ca V channel inhibition by RGKs. Our findings in cardiac myocytes suggest indeed functionally relevant differences between the two inhibitory mechanisms. Cardiac Ca V 1.2 channels are acutely up-regulated pharmacologically by agonists such as BAY K 8644 or physiological activation of PKA initiated by β-adrenergic agonists. The latter contributes to the fight-orflight response. Rem-inhibited Ca V 1.2 channels in heart cells can be overridden by BAY K 8644, indicating that the blocked channels remain at the cell surface (32) . However, both WT Rem-and Radinhibited channels are insensitive to PKA-mediated regulation (20, 32 coincidentally activated by membrane depolarization and PKAmediated phosphorylation. This paradigm could solve the conundrum of how a subset of Ca V 1.2 channels in heart cells might be reserved for signaling functions other than contraction, given that these channels are voltage-gated and the cardiac sarcolemma is subject to excitation with each heartbeat (33, 34) . In this regard, it is noteworthy that GDP-bound Rem and Rad have a lower affinity for Ca V β than their GTP-loaded counterparts (35) . We speculate that endogenous Rad toggles between BBD and BBI mechanisms to inhibit cardiac Ca V 1.2 channels dependent on the G domain being bound to GTP or GDP. Testing this proposition will be an interesting concept for future experiments.
Materials and Methods
Detailed methods are provided in SI Appendix, Materials and Methods.
Cell Culture and Transfection. Low-passage-number HEK293 cells were transiently transfected with Ca V α (6 μg), Ca V β (4 μg), T antigen (2 μg), and RGKs (4 μg) using the calcium-phosphate precipitation method.
Primary Cell Isolation and Culture. Primary cultures of adult guinea pig heart cells and murine DRG neurons were prepared and infected with adenovirus as described (14, 36, 37) . Procedures were in accordance with the guidelines of the Columbia University Animal Care and Use Committee.
Molecular Biology, Plasmids, and Adenoviral Vectors. Generation of XFP-tagged RGKs (Rad, Rem, Rem2, and Gem) and β 2a,TM has been previously described (12, 15) . Adenoviral vectors were generated using the AdEasy XL System (Stratagene) as previously described (38) .
Electrophysiology. Whole-cell recordings were carried out at room temperature on HEK293 cells 48 to 72 h after transfection as previously described (12) . Whole-cell currents were recorded from isolated ventricular myocytes as described (36, 39) .
Fluorescence Resonance Energy Transfer Imaging. We used three-cube FRET to probe protein-protein interactions (35) . Relative K d and E max values were calculated as previously described (35, 40) .
